Pharmacovigilance of quality deviations in the public healthcare system
Drug quality deviation (DQD) is the disagreement with the parameters at the registration with after commercialization step. Pharmacovigilance programs should be notified of DQD to ensure drug efficacy and support patient safety. Objective: To describe DQD from public healthcare system and its im...
Enregistré dans:
Auteurs principaux: | Carolina Resende Bitencourt, Cristiane Aparecida Menezes De Pádua, Paula Lana De Miranda Drummond, Edson Perini |
---|---|
Format: | article |
Langue: | EN PT |
Publié: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b5da99e20a1c4a8a97b339708dbc50ab |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Evidence-based Appraisal of the CARAVAGGIO Trial
par: Tiffany Khieu, et autres
Publié: (2021) -
Type 2 Diabetes Mellitus in Patients with a Prior History of Corticosteroid-induced Hyperglycemia
par: Jennifer Levine DeZubay, et autres
Publié: (2019) -
A proposal for pharmacovigilance data restructuring at the teaching hospital
par: Sayuri R. Yamashita, et autres
Publié: (2020) -
Guest editorial: The ten most important qualities for the profession of medicinal research
par: Tony Y. Zhang
Publié: (2021) -
Correction: Structural Racism and Supporting Black Lives – A Pharmacist’s Vow amid COVID-19
par: Nicole D. Avant
Publié: (2021)